Our Company

IMMETACYTE is a clinical-stage immuno-oncology company with an established, profitable GMP CDMO business for advanced cell therapies. Immetacyte’s patient-specific immunotherapy uses T-cells isolated from the patient’s tumour that are cancer specific and have been shown to home to the tumour and attack it – Tumour-Infiltrating Lymphocytes (TIL). The power of this truly specific TIL cell therapy against solid tumours was recognised by Immetacyte some years ago.

Our therapy is now clinically validated. Immetacyte has used TIL successfully to treat metastatic melanoma patients, some of whom have failed all other treatments (including checkpoint inhibitors). We have demonstrated that our therapy produces major tumour responses in 50% of patients and durable remissions and potential cures in around 20%.

We have built upon the expertise of researchers who have successfully undertaken scientific and clinical research alongside Professor Robert Hawkins. Professor Hawkins is a leader in the field having undertaken several complex research projects and clinical trials involving: TIL, CAR-T, TCR based T cell therapies, cell selection, gene therapy, expansion of patient derived cells.

Our clinical data act as a cornerstone for us to enter into a pivotal clinical trial in this indication. Having successfully treated melanoma we will move onto other solid tumour indications and next generation TIL-based products to build a pipeline of TIL-based therapies.

Management Team

Photo

Chief Executive Officer

Robert Hawkins is CEO at Immetacyte Ltd. Until recently, he was Cancer Research UK Professor at the University of Manchester/Christie Hospital, undertaking clinical and pre-clinical research and immuno-oncology, particularly cell therapy. From 2019 he became full time in Immetacyte Ltd to focus on the development of adoptive cell therapy focussed on the use of tumour infiltrating lymphocytes and next generation, gene engineered products in a range of solid tumours. Robert has extensive experience in biotechnology and cancer therapy. After a degree in mathematics from Trinity College, Cambridge and studying medicine at Cambridge and University College London, he undertook clinical training in Medical Oncology at the Royal Marsden Hospital and Addenbrookes Hospital. He subsequently undertook a PhD in Cambridge where he was an MRC Research Fellow with Sir Greg Winter and Dr Cesar Milstein at the MRC laboratory of Molecular Biology. His PhD was in antibody engineering – the methods he developed for affinity selection/maturation were important in the development of many therapeutic antibodies including Humira. As Cancer Research UK Senior Clinical Fellow, he developed translational research interests in antibody-based gene therapy and adoptive cell therapy. In 1998 he moved to the Christie Hospital to become Professor and Director of Medical Oncology. Clinically, his focus was the development of immunotherapies for kidney and other cancers. He led many trails of treatments for kidney cancer and also a range of early phase clinical trials of biological agents including vaccines, antibodies and cellular therapy. He is an author on the publications of several key practice changing trials in kidney cancer treatment. At the University of Manchester, he also led a group undertaking translational research into immunotherapy of cancer with a focus on adoptive cell therapy. Robert has also been the coordinator of several major European Union consortia in this field (the pre-clinical cell therapy ATTACK project and a cell therapy training network (ATTRACT) and an FP7 cell therapy clinical trials consortium (ATTACK). He has published widely in scientific and clinical journals (H-Index = 67) and is an inventor / co-inventor on several antibody and cell therapy related patents. He is / has been a member of many academic funding boards as well as numerous industry advisory boards. In 2008 he founded Cellular Therapeutics Ltd which has developed into Immetacyte Ltd and focusses on the commercial development of TIL based Adoptive Cell Therapy whilst Cellular Therapeutics Ltd continues as a contract manufacturer in the Cell Therapy space.
Photo

Chief Business Officer

Chairman, Immetacyte and Cellular therapeutics Ltd A serial entrepreneur with extensive operational, commercial, licensing and R&D background in academia, pharma and biotech companies. An immunologist, over the last thirty five years, in academia at NIMR, London and the University of London, and subsequently served on the Boards of biotech companies in the immunology and immune-oncology and gene therapy space. Currently as a Chairman of Immetacyte (Cellular therapeutics Ltd )and co-founder of Instil Inc., and co-founder and CEO of Trimunocor Ltd. Previously CBO of Biotecnol Ltd., with CMP Therapeutics Ltd as CEO, Roji Ltd as founder and CEO, Medigene AG (listed on the German Börse) as SVP Business Development and Commercial Strategy, Avidex Ltd (subsequently split into Immunocore and Adaptimune), as CBO, Oxford BioMedica plc (listed on the LSE), and BioMedica Inc as co-founder and EVP of Business development and Corporate Strategy and with Cambridge Genetics Ltd., the co-founder and CEO. As an Executive Director with P&L responsibilities, in listed (both the full London Stock Exchange (LSE) and the Alternative Investment Market) and private companies responsible for securing investments from private and public funds and completing numerous deals with pharmaceutical companies globally.
Photo

Chief Operating Officer

Chief Operating Officer and Co-founder of Immetacyte Ltd (formally Cellular Therapeutics) Dr Nicola Price has overseen operations of Immetacyte since its inception which has included the growth of the company from 4 founders to 25 employees, successful growth of CDMO revenue which has allowed the company to invest in its pipeline of TIL based products, including clinical application in Melanoma. She has also facilitated successful collaborations and partnerships with Pharmaceutical companies, academic institutions and biotech companies leading to licensing deals and grant funded projects which will see the company move to clinical trials in several oncology indications in the coming years, with the first trial opening summer 2019. Nicola assisted with the development of our current cell manufacturing facility which opened in 2011. It has enabled scale-up of autologous T cell therapy manufacturing. Between 2011 and 2015 she managed the transition from shared academic unit to independently owned and managed facility under Immetacyte Ltd. Nicola obtained a PhD in Cell Biology, supervised by Professor Mark Ferguson, at The University of Manchester. She worked as a Post-Doctoral researcher for several years, gaining commercial experience by leading projects jointly with SMEs, before taking the position of Project Manager for the University of Manchester's Gene and Immunotherapy Research Group in 2008. Nicola has managed several successful European Commission Framework Programme research projects, and overseen several successful grant funded project applications and research programmes
Photo

Director of Cell Production and Co-founder

Director of Cell Production and Co-founder of Immetacyte Ltd (formally Cellular Therapeutics) Ryan Guest one of the founders of Immetacyte and is Director of Cell Production. When Ryan entered the translational research field at the University of Manchester in 1998 he could hardly of anticipated that this was the start of a rewarding career through progressively senior roles spanning: basic cell therapy research in "CAR-T cell therapy"; ATMP product development and tech transfer; innovative GMP facility design and management; process technology development & implementation; quality & regulatory management; and in the last decade working with like-minded individuals to set-up Immetacyte Ltd (formerly Cellular therapeutics Ltd). To date Ryan has had the privilege and responsibility to develop and trial more than 5 types of Advanced Therapy Medicinal Products (ATMPs) using both gene engineered and natural personalised and allogenic cell therapies both in academia and through CMO contracts with industry-leading organisations. More recently, Ryan, represents Immetacyte as one of the industrial partners, by siting on the Innovate UK sponsored Advanced Therapy Treatment Centre Network (https://www.theattcnetwork.co.uk/) Steering committee as part of Immetacyte's involvement in iMATCH, MW-ATTC and SAMPLE which aiming to streamline the development and delivery of advanced cell based medicines in the UK. He originally received a BSc in Biological Sciences at the University of Swansea specialising in Immunology, Microbiology and Toxicology. After an industrial year (GSK, Research Triangle Park NC US) he returned to Swansea to complete his PhD and has authored a number of publications and patents in the field of T cell biology, ATMP development and manufacturing.
Photo

Director of Cell Therapy Research

Director of Cell Therapy Research of Immetacyte Ltd (formally Cellular Therapeutics) John undertook his PhD in 2004 under the supervision of Dr. David Gilham and Prof. Robert Hawkins at the University of Manchester. During this time his main interest was uncovering the signalling and molecular interactions of chimeric antigen receptors (CAR) and development of novel costimulatory CARs. John continued his research with Dr. Gilham and Prof Hawkins following his PhD, before a short period of research with Prof. Vaskar Saha at the University of Manchester studying CNS invasion in B-cell acute lymphoblastic leukaemia. In 2010 John moved to the labs of Prof. David Price and Prof. Andrew Sewell at Cardiff University where he focussed on T-cell receptor (TCR) gene transfer, using it as a tool to understand biological phenomena such as alloreactivity and TCR cross-reactivity, as well as further developing adoptive cell therapy strategies. In 2013 he was awarded a Wellcome Trust/NISCHR ISSF research fellowship within the Institute of Infection and Immunity at Cardiff University studying cross-reactivity profiles of virus specific T-cells
Photo

Director of Molecular Immunology Research

Dr Gray Kueberuwa PhD is the Director of Molecular Immunology Research at Immetacyte and an Honorary Research Fellow at The University of Manchester. He attained a Masters in Biochemistry and DPhil from the University of Oxford. His DPhil was focused on the development of Sindbis virus as an oncolytic agent, which he followed up with a 1-year fellowship to combine oncolytic virotherapy with Sindbis virus and Herpes virus 1 with immunotherapy through genetic modification to induce the production of secreted antibody fragments. Upon moving to The University of Manchester, he led projects developing tumour infiltrating lymphocyte (TIL) therapy and chimeric antigen receptor (CAR) T-cell therapy of cancer and the production of immune regulatory agents from within therapeutic cells. Gray then joined Immatacyte as the Director of Molecular Immunology Research.
Photo

Production Manager

Martine Thomas leads the production team at Immetacyte. She developed a keen interest in the response of the immune system to various conditions in the human body during her masters in Biomedical Sciences where she gained cell culture and immunology experience from researchers at University Medical Centre in Groningen and the University of Oxford’s John Radcliffe Hospital, before working at UCL with prof. John Wood for 3 years. Martine joined Immetacyte 5 years ago and became part of the team tasked with the manufacture and development of ATMPs. She has been involved in the production of TIL, CAR-T cells and TCR engineered T cells, and has a broad range of experience of working with both industry and academic organisations, transferring and developing manufacturing processes and bringing in new techniques using highly specialised equipment. She plays an important role in moving the development of TIL therapy forward and advancing into new clinical trials. GMP compliance is implemented throughout all stages of production and she has been involved in several MHRA and HTA inspections. This helps her to lead the expanding team of cell therapy production specialists to deliver therapeutic products to GMP standards, using aseptic techniques in clean room facilities
Photo

Finance Manager

Dawn joined Immetacyte in January 2019. A CIMA qualified accountant with over 25 years’ experience, Dawn has worked in many sectors, including Private Manufacturing, Public Sector, Housing and Charities. She has been involved in high value tendering exercises for specialised products for the Defence industry, a mutualisation, (following which Dawn went on to provide consultancy services on behalf of the group to assist other organisations who were also spinning out from councils to become mutual organisations), a merger, and a joint venture. This has included performing due diligence exercises, preparing and presenting Board reports and assisting with applications for funding. Dawn has led project teams implementing new systems and processes to develop statutory and internal reporting systems. She obtained a good knowledge of governance within the Charity and Housing Sectors.
Photo

Quality Manager

Roy Cowell is Quality Manager and Qualified Person at Immetacyte Ltd. Roy has extensive career experience in the manufacture of pharmaceuticals, initially with classical chemical entities and latterly with advanced therapy products. Roy is a Chemistry graduate holding Chartered status with the Royal Society of Chemistry and is nominated on the list of professionals eligible to act as Qualified Person, under the European Union Directives 2001/83/EC, 2001/82/EC and 2001/20/EC, maintained by the same. Roy joined Immetacyte Ltd at the beginning of 2016 following a role as Qualified Person for a commercial influenza vaccine manufacturer. Prior to this Roy has held positions with pharmaceutical manufacturers, both clinical and commercial, of chemical and advanced therapy medicines. These have been focussed on Quality and Regulatory aspects of manufacture under clinical trial or commercial manufacturing authorisations. Roy looks forward to delivering Quality Assured clinical products into trials that are aimed at demonstrating efficacy of cell based therapies as treatments for cancer, and future commercialisation making this type of cancer therapy available to all as a first line of treatment.
Photo

Clinical Pathways Programme Manager

Amu was born in Harbin in north eastern China and came to London in 2000 as a student to study for A levels, going on to study Biology at Imperial College, London. She then went on to obtain her PhD in T cell Immunology from Imperial College London in 2012. Following this, she was appointed as the Project Manager responsible for overseeing the delivery of a 5-year Programme Grant funded by the NIHR at the University of Liverpool/Royal Liverpool University Hospital. During this time, Amu led the delivery of 7 interlinked research projects in a matrix working environment involving partners from both public (universities, NHS Trusts, local GPs, NHS Clinical Commissioning Group), and service providers in the private sector. Amu has successfully managed the largest pragmatic trial in ophthalmology ever conducted in the UK with over 4500 participants. Amu has over 10 years of experience working in clinical research in academia and the NHS, including primary bench research and applied research in personalised medicine. Having made the transition from academia to industry, Amu joined Immetacyte in 2018 as the Clinical Pathway Programme Manager overseeing the delivery of clinical trials and several other IUK ATTC projects.

Board

Photo

Professor Robert Hawkins

Chief Executive Officer
Photo

Dr Neill Moray Mackenzie

Chairman - Non Exec
Photo

Dr Nicola Price

Chief Operating Officer
Photo

Dr Ryan Guest

Director of Cell Production and Co-founder

Partners

MW-ATTC
InnovateUK
Company